ROCK and Rho
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and usually fatal fibrotic disease of the distal lung alveolar gas exchange units.1King Jr., T.E. Pardo A. Selman M. Idiopathic pulmonary fibrosis.Lancet. 2011; 378: 1949-1961Abstract Full Text Full Text PDF PubMed Scopus (1376) Google Scholar IPF is typically diagnosed in older individuals, after the disease is well established. IPF patients experience progressive shortness of breath, reduced quality of life, and a median survival of only 2 to 3 years after diagnosis.2King Jr., T.E. Tooze J.A. Schwarz M.I. Brown K.R. Cherniack R.M. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.Am J Respir Crit Care Med. 2001; 164: 1171-1181Crossref PubMed Scopus (749) Google Scholar The disease burden is significant considering that the prevalence of disease in the United States is estimated to be between 14 and 42.7 cases per 100,000 individuals3Raghu G. Weycker D. Edelsberg J. Bradford W.Z. Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 2006; 174: 810-816Crossref PubMed Scopus (1008) Google Scholar and rising.4Gribbin J. Hubbard R.B. Le Jeune I. Smith C.J. West J. Tata L.J. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK.Thorax. 2006; 61: 980-985Crossref PubMed Scopus (452) Google Scholar Until the recent US Food and Drug Administration approval of pirfenidone and nintedanib, there were no effective therapies.5Richeldi L. du Bois R.M. Raghu G. Azuma A. Brown K.K. Costabel U. Cottin V. Flaherty K.R. Hansell D.M. Inoue Y. Kim D.S. Kolb M. Nicholson A.G. Noble P.W. Selman M. Taniguchi H. Brun M. Le Maulf F. Girard M. Stowasser S. Schlenker-Herceg R. Disse B. Collard H.R. INPULSIS Trial InvestigatorsEfficacy and safety of nintedanib in idiopathic pulmonary fibrosis.N Engl J Med. 2014; 370: 2071-2082Crossref PubMed Scopus (2824) Google Scholar, 6King Jr., T.E. Bradford W.Z. Castro-Bernardini S. Fagan E.A. Glaspole I. Glassberg M.K. Gorina E. Hopkins P.M. Kardatzke D. Lancaster L. Lederer D.J. Nathan S.D. Pereira C.A. Sahn S.A. Sussman R. Swigris J.J. Noble P.W. ASCEND Study GroupA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.N Engl J Med. 2014; 370: 2083-2092Crossref PubMed Scopus (2514) Google Scholar However, despite these recent breakthroughs, the outlook for IPF patients remains bleak, and there continues to be an urgent need for new therapies to impede disease progression and, more desirably, reverse established fibrosis. IPF is thought to develop in response to extensive and repetitive injury to the alveolar epithelial cells, resulting in apoptosis and the development of an abnormal repair response.7Noble P.W. Idiopathic pulmonary fibrosis: natural history and prognosis.Clin Chest Med. 2006; 27: S11-S16Abstract Full Text Full Text PDF PubMed Scopus (54) Google Scholar As is typical of wound repair in other sites, such as the skin, resident fibroblasts and myofibroblast progenitors proliferate and migrate to the injured lung parenchyma. In the transforming growth factor (TGF)-β–rich profibrotic microenvironment of the alveoli and interstitium, fibroblasts and myofibroblast progenitors express contractile proteins, such as α smooth muscle actin (α-SMA), ramp up production of extracellular matrix (ECM) proteins,8Kuhn 3rd, C. Boldt J. King Jr., T.E. Crouch E. Vartio T. McDonald J.A. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis.Am Rev Respir Dis. 1989; 140: 1693-1703Crossref PubMed Scopus (378) Google Scholar, 9Hoyles R.K. Derrett-Smith E.C. Khan K. Shiwen X. Howat S.L. Wells A.U. Abraham D.J. Denton C.P. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor beta receptor.Am J Respir Crit Care Med. 2011; 183: 249-261Crossref PubMed Scopus (93) Google Scholar and acquire a canonical myofibroblast phenotype. However, unlike normal resolving wound repair, in which myofibroblasts contract the newly synthesized provisional matrix, undergo apoptosis, and are cleared from the wound once repair is complete, lung myofibroblasts develop resistance to apoptosis induction, continue to produce excessive amounts of fibrotic ECM, and maintain their contractile properties in the lungs of IPF patients.10Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases.J Pathol. 2003; 200: 500-503Crossref PubMed Scopus (1270) Google Scholar Thus, a full understanding of the molecular mechanisms that control fibroblast–myofibroblast differentiation and their acquired resistance to apoptosis is essential to develop therapeutic approaches to reduce lung myofibroblast numbers, excessive ECM production, and tissue contraction in IPF patients. Studies reported by Sisson et al11Sisson T.H. Ajayi I.O. Subbotina N. Dodi A.E. Rodansky E.S. Chibucos L.N. Kim K.K. K
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310
Luchsinger, L. L., Patenaude, C. A., Smith, B. D., & Layne, M. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276931 · Cited by 127 · cited 1×
“During ROCK-1/2edependent F-actin assembly, MRTFs dissociate from G-actin, translocate to the nucleus, and coactivate serum response factoremediated transcription of fibronectin, procollagen 1, and other ECM genes.(15) Nuclear translocation of MRTFA also promotes the expression of a-SMA and antiapoptotic proteins B ce…”
Background
Cited by
Cutler, C., Lee, S. J., Arai, S., Rotta, M., Zoghi, B., Lazaryan, A., Ramakrishnan, A., DeFilipp, Z., Salhotra, A., Chai-Ho, W., et al. (2021) · Blood · doi:10.1182/blood.2021012021 · Cited by 354
ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease
Jagasia, M., Lazaryan, A., Bachier, C. R., Salhotra, A., Weisdorf, D. J., Zoghi, B., Essell, J., Green, L., Schueller, O., Patel, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02754 · Cited by 198
Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis
Huang, Y., Ma, S.-F., Espindola, M. S., Vij, R., Oldham, J. M., Huffnagle, G. B., Erb-Downward, J. R., Flaherty, K. R., Moore, B. B., White, E. S., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1525oc · Cited by 142
Zanin-Zhorov, A., & Blazar, B. R. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108823 · Cited by 74
Li, Q., Cheng, Y., Zhang, Z., Bi, Z., Ma, X., Wei, Y., & Wei, X. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1036 · Cited by 77
Nalkurthi, C., Schroder, W. A., Melino, M., Irvine, K. M., Nyuydzefe, M., Chen, W., Liu, J., Teng, M. W. L., Hill, G. R., Bertolino, P., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2021.100386 · Cited by 75
Metadata
- Authors
- Riches, D. W. H., Backos, D. S., & Redente, E. F.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 185
- Issue
- 4
- Pages
- 909-912
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W212348197
- Cited by
- 32
- References
- 5
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.